MNTA: Got it, thanks. I assumed you meant that analyst's would prematurely discount MNTA under the assumption that TEVA would get approval soon. I believe DD's best-case/worst-case with/without Sanofi's AG is very compelling and should be a must-read for the newbie analysts who materialized at the CC Friday.
I am happy regardless of any outcome because MNTA has been de-risked.
Can you imagine the possible impact if a Markman Summary Judgment is published in MNTA's favor?
"If we don't succeed, we run the risk of failure." -Dan Quayle